STOCK TITAN

AC Immune SA (ACIU) SEC Filings, May-Jun 2026

ACIU NASDAQ

AC Immune SA filings document a foreign private issuer developing precision therapeutics and diagnostics for neurodegenerative diseases. Recent Form 6-K reports furnish press releases, IFRS financial statements, management discussion and annual statutory and compensation reports, with certain reports incorporated by reference into Form F-3 and Form S-8 registration statements.

The disclosures cover clinical and trial updates for ACI-24, ACI-7104.056, ACI-19764 and ACI-35.030/JNJ-2056; collaboration amendments for Morphomer® Tau small molecules; cash resources and operating requirements; and governance-related compensation reporting. They also record exhibit-based material updates for AC Immune’s active immunotherapy, small-molecule and diagnostic pipeline.

Rhea-AI Summary

AC Immune SA director Roy Ervin Twyman received equity awards as compensation. On June 11, 2026 he was granted 16,568 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan, increasing his holdings to 92,556 common shares, including 66,556 shares underlying outstanding restricted share units.

On the same date he also received share options over 38,889 common shares with an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036, giving him the right to buy the underlying shares in the future rather than reflecting an open-market purchase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.30%
Tags
insider
-
Rhea-AI Summary

AC Immune SA director Renee Aguiar-Lucander reported equity compensation awards rather than open-market trades. On June 11, 2026, she received a restricted share unit grant covering 16,568 common shares under the AC Immune SA 2016 Stock Option and Incentive Plan.

Following this grant, 51,136 common shares are underlying her outstanding restricted share units. She was also awarded options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.30%
Tags
insider
-
Rhea-AI Summary

AC Immune SA interim CEO Martin Zuegel reported equity compensation awards. On June 11, 2026, he received a grant of 33,136 restricted share units under the company’s 2016 Stock Option and Incentive Plan. Following this award, he holds 71,408 common shares underlying outstanding restricted share units.

On the same date, he was also granted share options on 77,778 common shares at an exercise price of $2.6200 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. All reported holdings are direct.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.30%
Tags
insider
Rhea-AI Summary

AC Immune SA director Monika Buetler received new equity awards as part of her compensation. On June 11, 2026, she was granted 17,751 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan. The grant increases her direct interest in the company without any cash purchase.

On the same date, she also received share options for 41,667 common shares at an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. After these awards, she directly holds 71,656 common shares, largely reflecting restricted share units rather than open-market buying.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.30%
Tags
insider
-
Rhea-AI Summary

AC Immune SA director June Carl Howard reported new equity compensation grants. On June 11, 2026, she received 16,568 common shares as a restricted share unit grant under the AC Immune SA 2016 Stock Option and Incentive Plan.

Following this award, her direct holdings in common shares were 67,556. She also received share options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036. These awards reflect compensation rather than open‑market trading.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.30%
Tags
insider
-
Rhea-AI Summary

AC Immune SA reported that shareholders approved all proposals at the June 2026 Annual General Meeting, including the 2025 IFRS consolidated and statutory financial statements and the 2025 compensation report. Shareholders also discharged the Board and Executive Management and approved maximum compensation of CHF 1.029M for the Board and CHF 6.742M for Executive Management.

The company recorded a 2025 IFRS loss of CHF 70.4M on revenue of CHF 3.6M, increasing accumulated losses brought forward to CHF 424.441M. Liquidity was CHF 91.4M at year-end 2025 and CHF 74.8M as of March 31, 2026, supporting guidance for a cash runway into Q4 2027 with 2026 cash burn of CHF 55–65M. Shareholders approved a new capital band allowing share capital changes between CHF 2,202,018.50 and CHF 2,862,500.00 until June 11, 2031, and increased conditional share capital for employee plans to CHF 150,000.00 (up to 7.5 million shares). The AGM presentation highlighted an Alzheimer’s and Parkinson’s-focused pipeline, multiple FDA Fast Track designations and planned 2026 clinical milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
current report
Rhea-AI Summary

AC Immune SA reported that it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. The funding will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, its anti‑alpha‑synuclein active immunotherapy, in early Parkinson’s disease.

The company highlights that the extended trial will help generate long‑term safety and efficacy data, particularly for prodromal and early Parkinson’s disease where prolonged treatment is expected. Management describes ACI‑7104 as showing promising interim Phase 2 results with favorable safety, strong antibody responses, target engagement and encouraging clinical signals, with final Part 1 data to week‑104 expected in H2 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.60%
Tags
current report
-
Rhea-AI Summary

AC Immune SA Chief Executive Officer Andrea Pfeifer reported an open-market sale of 10,000 common shares. The trade occurred on May 15, 2026 at a weighted average price of $2.7935 per share, with individual prices ranging from $2.75 to $2.825.

After this sale, Pfeifer directly holds 3,820,288 common shares, which include 1,921,005 common shares underlying outstanding restricted share units. She also reports 14,000 common shares held indirectly by her spouse.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
insider
-
Rhea-AI Summary

AC Immune SA director and officer Andrea M.A. Pfeifer gave notice of a proposed sale of 20,000 common shares, with an aggregate market value of $56,000.00 and an approximate sale date of May 15, 2026. Her Rule 10b5-1 plan adoption date is March 27, 2025.

Pfeifer states the shares were acquired upon vesting of previously exercised stock options between June 1, 2012 and May 11, 2016. She also reports three earlier Rule 10b5-1 sales: 10,000 shares on February 17, March 16 and April 15, 2026, for gross proceeds of $28,693.00, $31,966.00 and $31,425.00, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
other
Rhea-AI Summary

AC Immune SA has called its 2026 Annual General Meeting for 11 June 2026 and published the invitation and proxy materials. Shareholders will vote on approval of the 2025 IFRS consolidated and statutory financial statements, the 2025 compensation report, loss appropriation, discharge of directors and executives, and binding maximum compensation for the Board and Executive Management.

The Board proposes Board compensation up to CHF 1,029,000 for the term from the 2026 AGM to the 2027 AGM and Executive Management compensation up to CHF 6,742,000 for 2027. Under IFRS, the consolidated net loss for 2025 was CHF 70,447K, with accumulated losses carried forward.

CEO Andrea Pfeifer will retire at the 2026 AGM after 23 years, and Chair Martin Zügel will serve as Interim CEO while remaining Chair. To reinforce governance, the Board appointed Monika Bütler as Lead Independent Director and added Carl June to the Audit & Finance Committee. Shareholders will also vote on introducing a capital band between CHF 2,202,018.50 and CHF 2,862,500.00 and increasing conditional share capital for employee plans to 7,500,000 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
current report

FAQ

How many AC Immune SA (ACIU) SEC filings are available on StockTitan?

StockTitan tracks 47 SEC filings for AC Immune SA (ACIU), including 20-F annual reports and 6-K reports. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for AC Immune SA (ACIU)?

The most recent SEC filing for AC Immune SA (ACIU) was filed on November 4, 2026.